The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.

The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.